专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2018209301A1 METHODS FOR TREATING OR PREVENTING GRAFT-VERSUS-HOST DISEASE INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS 审中-公开
公开(公告)号：WO2018209301A1
公开(公告)日：2018-11-15
申请号：PCT/US2018/032423
申请日：2018-05-11
申请人： CYTODYN INC.
发明人： BURGER, Denis, R.
IPC分类号： A61K39/395 , A61K31/7088 , A61P37/06
摘要： The present invention provides for inhibition or blockade of immunomodulatory cell receptors to treat or prevent graft-versus-host disease (GVHD). Thus, the invention relates generally to compositions and methods of using anti-CCR5 cell receptor binding agents, such as PRO 140, to treat or prevent GVHD.

2. 发明申请

WO2018209299A1 HUMANIZED MOUSE MODEL 审中-公开
公开(公告)号：WO2018209299A1
公开(公告)日：2018-11-15
申请号：PCT/US2018/032421
申请日：2018-05-11
申请人： CYTODYN INC.
发明人： BURGER, Denis, R.
IPC分类号： A01K67/027 , C12N5/0789 , C07K16/28
摘要： The present invention provides for inhibition or blockade of immunomodulatory cell receptors to facilitate improved or complete reconstitution of a human immune system in laboratory animals, improve animal health, and improve animal longevity. Thus, the invention relates generally to compositions and methods of generating and using transgenic non-human animals that are engrafted with a human hematopoietic system involving anti-CCR5 agents. In various embodiments, the human hematopoietic system engrafted transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, immune responses, vaccines and vaccination regimens, and human pathogens and production and collection of immune mediators, including human antibodies.

3. 发明申请

WO2021026028A1 METHODS FOR TREATING OR PREVENTING CANCERS INVOLVING THE ADMINISTRATION OF ANTI-CCR5 RECEPTOR AGENTS 审中-公开
公开(公告)号：WO2021026028A1
公开(公告)日：2021-02-11
申请号：PCT/US2020/044616
申请日：2020-07-31
申请人： CYTODYN INC.
发明人： BURGER, Denis , KELLY, Scott
IPC分类号： A61K39/395 , A61P35/04
摘要： The present disclosure relates to the use of competitive inhibitors of the CCR5 receptor, such as the monoclonal antibody leronlimab, or binding fragments thereof, in the treatment or prevention of cancer.

4. 发明申请

WO2014168933A1 FELINIZED ANTIBODIES AND METHODS OF TREATING RETROVIRAL INFECTIONS IN FELINES 审中-公开
标题翻译：治疗复发性感染的免疫抗体和方法
公开(公告)号：WO2014168933A1
公开(公告)日：2014-10-16
申请号：PCT/US2014/033300
申请日：2014-04-08
申请人： CYTODYN INC.
发明人： TRAUGER, Richard
IPC分类号： A61K39/395
CPC分类号： C07K16/2845 , A61K39/3955 , A61K45/06 , C07K2317/20 , C07K2317/24 , C07K2317/565 , C07K2317/76
摘要： Provided are felinized antibodies and methods for treating or reducing the likelihood of developing a retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline. These methods require the administration of at least one felinized antibody or fragment thereof that specifically binds to CD11a and/or CD18, or ICAM-1, and/or decreases or prevents the binding of LFA-1 (CD11a/CD18 heterodimer) to ICAM-1. Also provided are veterinary compositions and methods of identifying candidate agents useful for treating or reducing retroviral infection in a feline, decreasing retroviral virion entry into a feline cell, decreasing retroviral virion budding from a feline cell, or decreasing syncytium transmission in a feline.
摘要翻译：提供了用于治疗或降低在猫科动物中产生逆转录病毒感染的可能性的减毒抗体和方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。这些方法需要给予特异性结合CD11a和/或CD18或ICAM-1的至少一种有丝分裂的抗体或其片段，和/或降低或阻止LFA-1（CD11a / CD18异二聚体）与ICAM- 1。还提供了兽医组合物和鉴定可用于治疗或减少猫科动物中的逆转录病毒感染的候选物质的方法，减少逆转录病毒病毒体进入猫细胞，减少来自猫科动物细胞的逆转录病毒病毒体出芽，或减少猫科动物中的合胞体传播。

5. 发明申请

WO2020206026A1 ANTI-CCR5 AGENTS AND METHODS OF TREATMENT THAT BLOCK CANCER METASTASIS OR ENHANCE CELL DEATH INDUCED BY DNA DAMAGING CHEMOTHERAPY 审中-公开
公开(公告)号：WO2020206026A1
公开(公告)日：2020-10-08
申请号：PCT/US2020/026253
申请日：2020-04-01
申请人： CYTODYN INC. , KELLY, Scott
发明人： KELLY, Scott , PESTELL, Richard, G.
IPC分类号： C07K14/705 , C07K14/725 , C07K16/10
摘要： The present disclosure relates to the use of DNA damaging agents and leronlimab (PRO 140), or other anti-CCR5 agents, to treat or prevent cancer metastases and enhance the cell killing ability of the DNA damaging agents by selectively targeting the CCR5 receptor. The present disclosure relates to the use of DNA damaging agents and leronlimab (PRO 140), or other anti-CCR5 agents, to treat or prevent cancer metastases and reduce circulating tumor cells (CTC) or putative metastatic tumor cells in the peripheral blood following treatment,.reduce CCR5 expression on cancer-associated cells after following treatment, decrease volume in tumor size following treatment. The present disclosure may be used to treat or prevent subjects with cancer and, particularly, subjects with metastatic CCR5+ cancer.

6. 发明申请

WO2016210130A1 INHIBITION OF CCL5 LIGAND BINDING TO CCR5 RECEPTOR AND ALTERATION OF CCR5/CCL5 AXIS SIGNALING IN INFLAMMATION, CANCER, AUTOIMMUNE, AND OTHER CONDITIONS 审中-公开
标题翻译： CCL5配体绑定对CCR5受体的抑制和CCR5 / CCL5的轴突信号在炎症，癌症，自身免疫和其他条件下的信号传导
公开(公告)号：WO2016210130A1
公开(公告)日：2016-12-29
申请号：PCT/US2016/039016
申请日：2016-06-23
申请人： CYTODYN INC.
发明人： BURGER, Denis R.
IPC分类号： A61K31/7088 , A61K38/10 , A61K39/395
CPC分类号： A61K31/439 , A61K39/395
摘要： Methods for the therapeutic use of competitive inhibitors of the CCR5/CCL5 axis that express antagonist activity for RANTES (CCL5) for immunomodulatory treatment of subjects in need thereof. The competitive inhibitors may not have CCL5 agonist activity and can be used to inhibit, interrupt, block, mitigate, slow the progress of, and/or treat inflammation and/or various other CCR5/CCL5 axis signaling dependent down-stream activities associated with transplantation, including graft versus host disease, autoimmune disorders, infectious agents, chronic inflammation, and cancer, etc.
摘要翻译：治疗性使用表达RANTES（CCL5）拮抗剂活性的CCR5 / CCL5轴竞争性抑制剂用于免疫调节治疗有需要的受试者的方法。竞争性抑制剂可能不具有CCL5激动剂活性，并且可用于抑制，中断，阻断，减缓进展和/或治疗与移植相关的炎症和/或各种其它CCR5 / CCL5轴信号依赖性下游活动，包括移植物抗宿主病，自身免疫性疾病，感染因子，慢性炎症和癌症等。

7. 发明申请

WO2015126892A1 USE OF ANTI-CCR5 ANTIBODIES IN GRAFT VERSUS HOST DISEASE 审中-公开
标题翻译：在抗病毒性疾病中使用抗CCR5抗体
公开(公告)号：WO2015126892A1
公开(公告)日：2015-08-27
申请号：PCT/US2015/016294
申请日：2015-02-18
申请人： CYTODYN INC
发明人： MONTGOMERY, Alan B.
IPC分类号： A61K39/00 , A61K39/395 , A61P29/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K9/0053 , A61K31/351 , A61K31/46 , A61K31/496 , A61K31/506 , A61K31/55 , A61K39/39541 , A61K45/06 , C07K16/2866 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/76 , C07K2317/92 , A61K2300/00
摘要： This composition and method provides for a method for reducing GVHD in a human subject which comprises administering to the subject at a predefined interval effective GVHD-reducing doses of (a) a humanized antibody designated PRO 140, or of (b) an anti-CCR5 receptor monoclonal antibody. This invention also provides a method for inhibiting in a human subject the onset or progression of GVHD. This invention also provides a method for treating a subject with GVHD comprising administering to the subject (a) a monoclonal antibody which (i) binds to a CCR5 receptor on the surface of the subject's CD4.sup.+ cells, and (b) a non-antibody CCR5 receptor antagonist, in amounts effective to treat the subject.
摘要翻译：该组合物和方法提供了用于减少人受试者中的GVHD的方法，其包括以预定间隔向受试者施用有效的GVHD减少剂量的（a）命名为PRO 140的人源化抗体或（b）抗CCR5 受体单克隆抗体。本发明还提供了抑制人受试者GVHD发病或进展的方法。本发明还提供用于治疗患有GVHD的受试者的方法，其包括向受试者施用（a）单克隆抗体，所述单克隆抗体（i）结合受试者的CD4 +细胞的表面上的CCR5受体，和（b）非抗体CCR5受体拮抗剂，其量有效治疗受试者。

8. 发明申请

WO2021146323A1 CCR5 BINDING AGENT FOR TREATMENT OF CCR5 POSITIVE METASTATIC CANCER 审中-公开
公开(公告)号：WO2021146323A1
公开(公告)日：2021-07-22
申请号：PCT/US2021/013289
申请日：2021-01-13
申请人： CYTODYN INC.
发明人： KELLY, Scott
IPC分类号： C07K14/705 , C07K14/725 , C07K16/10 , A61K2039/505 , A61K2039/507 , A61K31/167 , A61K31/282 , A61K31/337 , A61K31/4025 , A61K31/4196 , A61K31/4545 , A61K31/499 , A61K31/506 , A61K39/39541 , A61K39/3955 , A61K39/39558 , A61P35/04 , C07K16/2866 , C07K2317/24 , C07K2317/565
摘要： The present disclosure relates to the use of CCR5 binding agents, such as the leronlimab, in the treatment or prevention of CCR5+ metastatic cancer. Presented herein are methods for treating a subject for metastatic breast cancer by administering to the subject an effective amount of a CCR5 binding agent, such as leronlimab.

9. 发明申请

WO2019055995A1 SCREENING METHODS FOR IDENTIFYING AND TREATING HIV-1 INFECTED PATIENT SUB-POPULATIONS SUITABLE FOR LONG TERM ANTI-CCR5 AGENT THERAPY 审中-公开
公开(公告)号：WO2019055995A1
公开(公告)日：2019-03-21
申请号：PCT/US2018/051536
申请日：2018-09-18
申请人： CYTODYN INC. , MADDON, Paul , POURHASSAN, Nader
发明人： MADDON, Paul , POURHASSAN, Nader
IPC分类号： C07K16/28 , A61P31/18 , A61K39/00
CPC分类号： C07K16/2866 , A61K2039/505 , A61K2039/545 , C07K2317/24 , G01N33/56988 , G01N2333/16
摘要： Certain R5 virus tropic HIV-1 subjects with viral load effectively conventionally controlled using HAART, i.e., subject having less than 50 viral copies/mL (

10. 发明申请

WO2013040188A1 ANTI-CD11A ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗CD11A抗体及其用途
公开(公告)号：WO2013040188A1
公开(公告)日：2013-03-21
申请号：PCT/US2012/055132
申请日：2012-09-13
申请人： CYTODYN, INC. , TRAUGER, Richard , FLEISCHAKER, Robert
发明人： TRAUGER, Richard , FLEISCHAKER, Robert
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2845 , C07K2317/24 , C07K2317/56 , C07K2317/92
摘要： Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments.
摘要翻译：本文提供了与CD11a特异性结合的分离的人，嵌合和人源化抗体及其抗原结合片段。还提供了在具有HIV感染或AIDS的受试者中治疗人类免疫缺陷病毒（例如，降低发展或预防HIV感染或AIDS发展的风险）的方法，包括施用至少一种抗体或抗原结合片段到主题。还提供了在细胞表面上交联CD11a的方法，其包括使细胞与至少一种抗体或抗原结合片段接触。还提供含有至少一种抗体或抗原结合片段的组合物（例如，药物组合物）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式